ENXTAM:LKFTBiotechs
Lakefront Refocuses On T Cell Engagers With Gilead Partnership Pivot
Lakefront Biotherapeutics (ENXTAM:LKFT) has completed its acquisition of Ouro Medicines.
The deal adds gamgertamig, a BCMAxCD3 T cell engager, to Lakefront's pipeline.
Through a partnership with Gilead Sciences, gamgertamig is being advanced toward registrational studies targeted for 2027.
Lakefront Biotherapeutics enters this phase with its shares at €24.08 and a mixed recent track record, including a decline of 39.1% over three years and 63.6% over five years. In that context, the Ouro...